DrugPatentWatch Database Preview

Details for Patent: 8,158,601

« Back to Dashboard

Which drugs does patent 8,158,601 protect, and when does it expire?

Patent 8,158,601 protects ONPATTRO and is included in one NDA.

This patent has forty-five patent family members in twenty-one countries.

Summary for Patent: 8,158,601

Title:	Lipid formulation
Abstract:	The invention features a cationic lipid of formula I, ##STR00001## an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
Inventor(s):	Chen; Jianxin (Cambridge, MA), Ansell; Steven (Cambridge, MA), Akinc; Akin (Cambridge, MA), Dorkin; Joseph Robert (Cambridge, MA), Qin; Xiaojun (Cambridge, MA), Cantley; William (Cambridge, MA), Manoharan; Muthiah (Cambridge, MA), Rajeev; Kallanthottathil G. (Cambridge, MA), Narayanannair; Jayaprakash K. (Cambridge, MA), Jayaraman; Muthusamy (Cambridge, MA)
Assignee:	Alnylam Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	12/813,448
Patent Claim Types: see list of patent claims	Use; Formulation; Compound; Delivery;

Drugs Protected by US Patent 8,158,601

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alnylam Pharms Inc	ONPATTRO	patisiran sodium	SOLUTION;INTRAVENOUS	210922-001	Aug 10, 2018		RX	Yes	Yes			Y			TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS

International Family Members for US Patent 8,158,601

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010259984
Australia	2017202702
Australia	2019204984
Canada	2764609